FY2028 EPS Estimate for Exelixis Increased by Analyst

Posted by on Oct 9th, 2026

Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Investment analysts at Zacks Research raised their FY2028 earnings per share (EPS) estimates for shares of Exelixis in a research report issued on Thursday, October 8th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $4.22 per share for the year, up from their previous forecast of $4.21. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.19 per share.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The firm’s revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $0.75 earnings per share.

EXEL has been the subject of several other reports. Truist Financial lifted their price objective on shares of Exelixis from $52.00 to $54.00 and gave the company a “hold” rating in a research note on Wednesday. Barclays upped their price objective on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada lowered their target price on shares of Exelixis from $46.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday. Morgan Stanley lifted their price target on Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a research note on Thursday, July 23rd. Finally, Wells Fargo & Company increased their price target on Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $50.36.

Read Our Latest Stock Analysis on EXEL

Exelixis Trading Up 1.0%

NASDAQ:EXEL opened at $59.02 on Friday. Exelixis has a twelve month low of $33.76 and a twelve month high of $61.14. The company has a market cap of $14.62 billion, a PE ratio of 18.56, a P/E/G ratio of 1.74 and a beta of 0.47. The company’s 50 day moving average is $56.13 and its two-hundred day moving average is $52.15.

Insider Buying and Selling

In other news, Director Mary Beckerle sold 9,812 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the transaction, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. This represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Exelixis

Several hedge funds have recently made changes to their positions in the business. Private Client Services LLC boosted its position in shares of Exelixis by 0.7% during the third quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock worth $1,667,000 after buying an additional 209 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in Exelixis by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after acquiring an additional 281 shares during the period. Fifth Third Wealth Advisors LLC increased its position in Exelixis by 3.8% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock valued at $389,000 after acquiring an additional 333 shares during the period. Chicago Partners Investment Group LLC raised its stake in Exelixis by 2.8% during the 1st quarter. Chicago Partners Investment Group LLC now owns 16,204 shares of the biotechnology company’s stock valued at $759,000 after acquiring an additional 442 shares in the last quarter. Finally, Allworth Financial LP raised its stake in Exelixis by 4.7% during the 2nd quarter. Allworth Financial LP now owns 10,562 shares of the biotechnology company’s stock valued at $575,000 after acquiring an additional 478 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

  • Positive Sentiment: Zacks slightly raises long-term earnings forecast: Zacks Research increased its FY2028 EPS estimate for Exelixis to $4.22 from $4.21. Although the adjustment is modest and the firm maintains a “Hold” rating, the revision indicates stable expectations for future profitability. Zacks Research earnings estimate update
  • Positive Sentiment: Some valuation commentary remains favorable: Coverage highlighted Exelixis as a potential value stock, while another analysis suggested the shares may be undervalued as investors focus on earnings and the company’s continued growth. Exelixis’ latest quarterly results showed earnings above expectations and revenue growth of 10.6% year over year. Zacks value stock analysis Exelixis may be undervalued analysis
  • Neutral Sentiment: Truist raises its target but remains cautious: Truist Financial lifted its price target from $52 to $54 while retaining a “Hold” rating. The increase is supportive, but the new target still implies approximately 8.5% downside from the referenced share price. Truist raises Exelixis price target
  • Negative Sentiment: RBC cuts its price target: Royal Bank of Canada reduced its target to $45 from $46 and kept a “Sector Perform” rating. The target implies roughly 23.8% downside, reinforcing concerns that the shares may be fully valued at current levels. RBC cuts Exelixis price target
  • Negative Sentiment: Cabozantinib patent timing remains an overhang: Investors are assessing whether Exelixis’ valuation fully reflects the remaining patent protection for its key cancer drug, cabozantinib. Potential future patent-related erosion could limit upside and is contributing to caution around the stock. Exelixis cabozantinib patent analysis

About Exelixis

(Get Free Report)

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California.

Featured Articles

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.